Company / AR per Share
NEKTAR THERAPEUTICS AR per Share History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest AR per Share
$0.01
FY2023
5-year range
$0.01 / $0.12
FY2019-FY2023
Trend
-80.2%
vs FY2022
Sector context
#110 of 115
Health Care
What the data says
Among 115 Health Care companies, NEKTAR THERAPEUTICS is in the bottom 4% for ar per share. AR per Share has declined for 3 consecutive years, from $0.22 in FY2020 to $0.01 in FY2023.
Based on SEC 10-K filings.
0.01 in FY2023 with a 5-year CAGR of -52.7%.
Declined from $0.12 to $0.01 over the past 2 years.
Health Care sector context is included.
AR per Share over time
Growth rates
- 3-Year CAGR
- -69.3%
- 5-Year CAGR
- -52.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 115This company $0.01 Sector average $27.05
▼
-100.0% below sector average
Key checks
Key Insights
- NEKTAR THERAPEUTICS's ar per share has declined for 3 consecutive years.
- In FY2023, ar per share decreased 80.2% year-over-year.
- Ranks #110 out of 115 companies in the Health Care sector.
- Peak ar per share was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score -11.97 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | AR per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $0.01 | -80.2% |
| FY2022 | $0.03 | -74.2% |
| FY2021 | $0.12 | -43.3% |
| FY2020 | $0.22 | +3.9% |
| FY2019 | $0.21 | -21.7% |
| FY2018 | $0.27 | +727.7% |
| FY2017 | $0.03 | -71.8% |
| FY2016 | $0.12 | -23.8% |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026